by Ket Patel | Oct 15, 2012 | All Articles For Neurology, Alzheimer's Disease, Latest Articles
The imaging agent florbetapir F 18 injection (Amyvid), used to exclude a diagnosis of Alzheimer’s disease, is being evaluated for Medicare reimbursement, the Centers for Medicare and Medicaid Services has announced. The agency stated on Oct. 9 that it expected a...
by Ket Patel | Oct 11, 2012 | All Articles For Neurology, Headache/Migraine
Headache medicine specialists have used onabotulinumtoxinA off label as an efficacious treatment for headache prophylaxis for a number of years. The pooled results from the double-blind, randomized, placebo-controlled, Phase III Research Evaluating Migraine...
by Ket Patel | Oct 9, 2012 | Slider Content
Twenty-five percent of chronic migraine patients experience at least a 75% reduction in headache days per month after 6 months of treatment with onabotulinumtoxinA, according to a new analysis of data from the landmark PREEMPT trials. “That’s what I tell my...
by Ket Patel | Oct 9, 2012 | Latest Articles
Brief low-temperature radiofrequency rhizolysis of the C-1 spinal nerve and C-2 and C-3 dorsal root ganglia was safe and effective for occipital neuralgia with migraine in a retrospective series of 10 patients. “The pain reduction lasted for an average of 5½...
by Ket Patel | Oct 5, 2012 | All Articles For Neurology, Headache/Migraine
Twenty-five percent of chronic migraine patients experience at least a 75% reduction in headache days per month after 6 months of treatment with onabotulinumtoxinA, according to a new analysis of data from the landmark PREEMPT trials. “That’s what I tell my...
